Advertisement
Home Tags Psoriasis

Tag: Psoriasis

Twice-weekly certolizumab biologic appears to be both safe and effective for the treatment of moderate-to-severe chronic plaque psoriasis

Certolizumab Looks Promising for Moderate-to-Severe Psoriasis

0
Higher-dose certolizumab (400 mg) better at cutting symptoms than low-dose (200 mg)
Patients with psoriasis commonly report poor sleep

Psoriasis Negatively Affects Patient Sleep Quality

0
Psoriasis patients self-report worse sleep quality compared to healthy controls; itch main predictor
A smartphone app is associated with improved short-term adherence to a cutaneous foam treatment for psoriasis

Phone App Linked to Improved Psoriasis Treatment Adherence

0
App intervention group also had greater reduction in psoriasis severity than non-intervention group
Ustekinumab improves psoriasis and reduces vascular inflammation among patients with moderate-to-severe psoriasis

AAD: Ustekinumab Cuts Vascular Inflammation in Psoriasis

0
Reduction in total aortic vascular inflammation with ustekinumab versus increase with placebo
For patients with psoriasis

Patient-Initiated Consultations Beneficial in Psoriasis

0
No difference seen in Dermatology Life Quality Index versus routine care but fewer consultation requests
A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described in a research letter published online Jan. 16 in the Annals of Internal Medicine.

Psoriasis Remission Described After Hepatitis C Virus Treatment

0
Case report: After initiation of ledipasvir-sofosbuvir, HCV RNA decreased, and skin lesions improved
Children with psoriasis have an increased risk of comorbidities compared to children without psoriasis

Psoriasis Is Independent Risk Factor for Comorbidity in Children

0
Those with psoriasis at higher risk for diabetes, liver disease, elevated lipid levels independent of obesity

The American College of Rheumatology, Nov. 3-8

0
The 81st Annual Meeting of the American College of Rheumatology The annual meeting of the American College of Rheumatology was held...
For patients with active psoriatic arthritis who have an inadequate response to tumor necrosis factor inhibitors or to conventional synthetic disease-modifying antirheumatic drugs

Tofacitinib Superior to Placebo in Active Psoriatic Arthritis

0
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis

Secukinumab Effective for Moderate/Severe Scalp Psoriasis

0
Over half of patients have 90 percent improvement on Psoriasis Scalp Severity Index score